YD Bio Limited (YDES)
NASDAQ: YDES · Real-Time Price · USD
13.91
+1.13 (8.89%)
At close: Dec 5, 2025, 4:00 PM EST
14.18
+0.28 (1.98%)
After-hours: Dec 5, 2025, 7:47 PM EST
Company Description
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
The company is based in Taipei, Taiwan.
Contact Details
Address: No. 3, Xingnan St., 12F. Taipei, 115001 Taiwan | |
| Website | ydesgroup.com |
Stock Details
| Ticker Symbol | YDES |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002011674 |
| CUSIP Number | G98301107 |
| ISIN Number | KYG983011076 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. J. Douglas Ramsey Jr., Ph.D. | Chairman, Chief Executive Officer and Chief Financial Officer |
| Russell D. Griffin | President and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | 424B3 | Prospectus |
| Nov 17, 2025 | 6-K | Report of foreign issuer |
| Oct 24, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 30, 2025 | 6-K | Report of foreign issuer |
| Sep 26, 2025 | 6-K | Report of foreign issuer |
| Sep 23, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Sep 19, 2025 | 6-K | Report of foreign issuer |
| Sep 5, 2025 | 20FR12B | Filing |
| Aug 28, 2025 | CERT | Certification by an exchange approving securities for listing |
| Aug 20, 2025 | 8-A12B | Registration of securities |